GlassScriptPhysician profile
John N Sanderson
NPI 1841290178
$2,997.28
in general payments reported to CMS, 2019-2025
23 companies · $35.05 in 2025
The $35.05 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $461 · 2020: $590 · 2021: $643 · 2022: $449 · 2023: $609 · 2024: $209 · 2025: $35.05.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $854.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $853.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $712.12 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $534.12 | 2019-2024 | |
| Boston Scientific Corporation | $240.51 | 2019-2023 | Watchman Flx, Watchman Access System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $236.41 | 2020-2023 | Jardiance |
| Merck Sharp & Dohme LLC | $213.10 | 2021-2023 | Verquvo |
| Janssen Pharmaceuticals, INC | $191.11 | 2019-2023 | Xarelto |
| Allergan, INC. | $179.61 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $179.38 | 2023-2024 | Lifevest |
| Actelion Pharmaceuticals US, INC. | $70.64 | 2019-2024 | Opsumit, Uptravi |
| Abbvie INC. | $68.62 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $63.97 | 2019 | |
| Galderma Laboratories, L.P. | $42.20 | 2019-2021 | |
| Amgen INC. | $34.97 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.94 | 2021 | |
| Irhythm Technologies, INC. | $33.50 | 2024 | Zio Monitor, Zio Xt Patch |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $30.13 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $25.65 | 2019-2021 | |
| Alnylam Pharmaceuticals INC. | $24.94 | 2023 | Onpattro |
| Itamar Medical INC | $23.43 | 2023 | Watchpatone |
| Scpharmaceuticals INC. | $18.37 | 2024 | |
| Esperion Therapeutics, INC. | $14.54 | 2023 | Nexletol |
| Pfizer INC. | $13.17 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $12.85 | 2023 | Inpefa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Sanderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.